title: New tuberculosis drug development. How can we do better?
authors.forename: R J
authors.initials: RJ
authors.lastname: O'Brien
authors.forename: A A
authors.initials: AA
authors.lastname: Vernon
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry; D024841:Fluoroquinolones; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000592:standards; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D012293:Rifampin; C018421:rifapentine